Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including:
Scott R. Plotkin, MD, PhD
Pappas Center for Neuro-Oncology
Professor of Neurology
Harvard Medical School
Brian D. Weiss, MD
Clinical Professor of Pediatrics
Cancer and Blood Diseases Institute Division of Oncology
Solid Tumor Program
Cincinnati Children’s Hospital Medical Center
Expert commentary from Dr. Scott R. Plotkin on using MEK inhibitors for neurofibromatosis 1 (NF1), from Clinical Care Options (CCO)
On-demand webcast on plexiform neurofibromas in neurofibromatosis type 1 (NF1) featuring 2 faculty experts presented by Clinical Care Options (CCO)
Downloadable PDF with highlights from a CCO podcast on managing neurofibromatosis type 1 and MEK inhibitors plexiform neurofibromas.
Downloadable slideset covering MEK inhibitors for plexiform neurofibromas in patients with NF1, from Clinical Care Options (CCO)